Literature DB >> 25556339

False discovery rates for rare variants from sequenced data.

Marinela Capanu1, Venkatraman E Seshan.   

Abstract

The detection of rare deleterious variants is the preeminent current technical challenge in statistical genetics. Sorting the deleterious from neutral variants at a disease locus is challenging because of the sparseness of the evidence for each individual variant. Hierarchical modeling and Bayesian model uncertainty are two techniques that have been shown to be promising in pinpointing individual rare variants that may be driving the association. Interpreting the results from these techniques from the perspective of multiple testing is a challenge and the goal of this article is to better understand their false discovery properties. Using simulations, we conclude that accurate false discovery control cannot be achieved in this framework unless the magnitude of the variants' risk is large and the hierarchical characteristics have high accuracy in distinguishing deleterious from neutral variants.
© 2014 WILEY PERIODICALS, INC.

Entities:  

Keywords:  false discovery rate; hierarchical model; local false discovery rate; rare variants

Mesh:

Year:  2014        PMID: 25556339      PMCID: PMC4711769          DOI: 10.1002/gepi.21880

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  24 in total

1.  Accounting for human polymorphisms predicted to affect protein function.

Authors:  Pauline C Ng; Steven Henikoff
Journal:  Genome Res       Date:  2002-03       Impact factor: 9.043

2.  Pooled association tests for rare variants in exon-resequencing studies.

Authors:  Alkes L Price; Gregory V Kryukov; Paul I W de Bakker; Shaun M Purcell; Jeff Staples; Lee-Jen Wei; Shamil R Sunyaev
Journal:  Am J Hum Genet       Date:  2010-05-13       Impact factor: 11.025

3.  Incorporating model uncertainty in detecting rare variants: the Bayesian risk index.

Authors:  Melanie A Quintana; Jonine L Berstein; Duncan C Thomas; David V Conti
Journal:  Genet Epidemiol       Date:  2011-08-26       Impact factor: 2.135

4.  FDR-controlling testing procedures and sample size determination for microarrays.

Authors:  Shuying S Li; Jeannette Bigler; Johanna W Lampe; John D Potter; Ziding Feng
Journal:  Stat Med       Date:  2005-08-15       Impact factor: 2.373

5.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.

Authors:  S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas
Journal:  J Med Genet       Date:  2005-07-13       Impact factor: 6.318

6.  Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling.

Authors:  Marinela Capanu; Patrick Concannon; Robert W Haile; Leslie Bernstein; Kathleen E Malone; Charles F Lynch; Xiaolin Liang; Sharon N Teraoka; Anh T Diep; Duncan C Thomas; Jonine L Bernstein; Colin B Begg
Journal:  Genet Epidemiol       Date:  2011-04-25       Impact factor: 2.135

7.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

8.  Incorporating prior biologic information for high-dimensional rare variant association studies.

Authors:  Melanie A Quintana; Fredrick R Schumacher; Graham Casey; Jonine L Bernstein; Li Li; David V Conti
Journal:  Hum Hered       Date:  2013-04-11       Impact factor: 0.444

9.  A new testing strategy to identify rare variants with either risk or protective effect on disease.

Authors:  Iuliana Ionita-Laza; Joseph D Buxbaum; Nan M Laird; Christoph Lange
Journal:  PLoS Genet       Date:  2011-02-03       Impact factor: 5.917

10.  An evaluation of statistical approaches to rare variant analysis in genetic association studies.

Authors:  Andrew P Morris; Eleftheria Zeggini
Journal:  Genet Epidemiol       Date:  2010-02       Impact factor: 2.135

View more
  1 in total

1.  The prognostic effects of somatic mutations in ER-positive breast cancer.

Authors:  Obi L Griffith; Nicholas C Spies; Meenakshi Anurag; Malachi Griffith; Jingqin Luo; Dongsheng Tu; Belinda Yeo; Jason Kunisaki; Christopher A Miller; Kilannin Krysiak; Jasreet Hundal; Benjamin J Ainscough; Zachary L Skidmore; Katie Campbell; Runjun Kumar; Catrina Fronick; Lisa Cook; Jacqueline E Snider; Sherri Davies; Shyam M Kavuri; Eric C Chang; Vincent Magrini; David E Larson; Robert S Fulton; Shuzhen Liu; Samuel Leung; David Voduc; Ron Bose; Mitch Dowsett; Richard K Wilson; Torsten O Nielsen; Elaine R Mardis; Matthew J Ellis
Journal:  Nat Commun       Date:  2018-09-04       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.